| Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma RW Merryman, L Castagna, L Giordano, VT Ho, P Corradini, A Guidetti, ... Leukemia 35 (9), 2672-2683, 2021 | 63 | 2021 |
| Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas J Svoboda, SM Bair, DJ Landsburg, SD Nasta, SJ Nagle, SK Barta, ... Haematologica 106 (6), 1705, 2021 | 56 | 2021 |
| Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, ... Annals of Oncology 33 (9), 916-928, 2022 | 50 | 2022 |
| Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma RW Merryman, RA Redd, T Nishihori, J Chavez, Y Nieto, JM Darrah, ... Blood Advances 5 (6), 1648-1659, 2021 | 40 | 2021 |
| Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer YG Lee, P Guruprasad, G Ghilardi, R Pajarillo, CT Sauter, R Patel, ... Cancer discovery 12 (10), 2372-2391, 2022 | 38 | 2022 |
| A characterization of bridging therapies leading up to commercial CAR T-cell therapy SD Nasta, ME Hughes, EC Namoglu, DJ Landsburg, EA Chong, SK Barta, ... Blood 134, 4108, 2019 | 20 | 2019 |
| Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma VM Orellana-Noia, K Isaac, MK Malecek, NL Bartlett, TJ Voorhees, ... Blood advances 5 (18), 3623-3632, 2021 | 18 | 2021 |
| CRISPR-Cas9 knock out of CD5 enhances the anti-tumor activity of chimeric antigen receptor T cells I Chun, KH Kim, YH Chiang, W Xie, YGG Lee, R Pajarillo, A Rotolo, ... Blood 136, 51-52, 2020 | 17 | 2020 |
| Hospitalization patterns with commercial CAR T-cell therapy: a single institution experience SD Nasta, EC Namoglu, ME Hughes, EA Chong, J Svoboda, HJ Ballard, ... Blood 134, 3240, 2019 | 16 | 2019 |
| Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel JT Romancik, S Goyal, JN Gerson, HJ Ballard, Y Sawalha, DA Bond, ... Blood 138, 1756, 2021 | 15 | 2021 |
| Use of bendamustine for lymphodepletion before tisagenlecleucel (anti-CD19 CAR T cells) for aggressive B-cell lymphomas J Svoboda, HJ Ballard, EA Chong, MI LaRose, SM Bair, EC Namoglu, ... Blood 134, 1606, 2019 | 12 | 2019 |
| 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma A Ruff, HJ Ballard, AR Pantel, EC Namoglu, ME Hughes, SD Nasta, ... Molecular imaging and biology 23, 818-826, 2021 | 11 | 2021 |
| Safety and efficacy of allogeneic hematopoietic stem cell transplant after programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) blockade for classical Hodgkin … RW Merryman, L Castagna, P Corradini, VT Ho, DA Bond, S Jaglowski, ... Blood 134, 775, 2019 | 11 | 2019 |
| Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines G Ghilardi, L Paruzzo, J Svoboda, EA Chong, AA Shestov, L Chen, ... Blood Advances 8 (3), 653-666, 2024 | 9 | 2024 |
| Outcomes of tisagenlecleucel in lymphoma patients with predominant management in an ambulatory setting SD Nasta, ME Hughes, EC Namoglu, A Garfall, H DiFilippo, HJ Ballard, ... Clinical Lymphoma Myeloma and Leukemia 22 (8), e730-e737, 2022 | 9 | 2022 |
| Everolimus plus itacitinib in relapsed/refractory classical Hodgkin lymphoma: results of a phase I/II investigator initiated trial (EVITA study) J Svoboda, SK Barta, DJ Landsburg, SD Nasta, WT Hwang, G Delp, ... Blood 136, 20-21, 2020 | 7 | 2020 |
| Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer. Cancer Discov 2022; 12: 2372–91. doi: 10.1158/2159 … YG Lee, P Guruprasad, G Ghilardi, R Pajarillo, CT Sauter, R Patel, ... CD-21-1026, 0 | 7 | |
| Advances and personalized approaches in the frontline treatment of T-cell lymphomas MG Angelos, HJ Ballard, SK Barta Journal of Personalized Medicine 12 (2), 267, 2022 | 6 | 2022 |
| Bendamustine is a safe and effective regimen for lymphodepletion before tisagenlecleucel in patients with large B-cell lymphomas G Ghilardi, EA Chong, J Svoboda, P Wohlfarth, SD Nasta, S Williamson, ... Blood 138, 1438, 2021 | 5 | 2021 |
| Outcome of autologous stem cell transplantation following PD-(L) 1 based salvage therapy for multiply relapsed patients with classic Hodgkin lymphoma RW Merryman, RA Redd, Y Nieto, U Rao, MT Byrne, DA Bond, ... Blood 134, 4571, 2019 | 4 | 2019 |
Jakub SvobodaUniversity of Pennsylvania在 uphs.upenn.edu 的电子邮件经过验证
Jakub SvobodaUniversity of Pennsylvania在 uphs.upenn.edu 的电子邮件经过验证